AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's presentation from the pain conference IASP 2022 is now available in its entirety on the company's website. The abstract includes new results from the company’s preclinical project TrkA-NAM, which is developed with a focus on osteoarthritis pain and other severe pain conditions.
The presentation, titled Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA, was held by the project manager Dr. Pontus Forsell and contains new results from the ongoing preclinical studies with a substance in the TrkA-NAM project. They include effect studies in a pain model, but also studies on inflammation and relevant biomarkers.
The results show that the substance, AC-0027838, has a potent analgesic effect in a model of nociceptive pain. The substance blocks NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation regarding its role in pain. The data also show that AC-0027838 has a powerful anti-inflammatory effect, something that may potentiate its analgesic effects in clinical contexts. Analysis of the inflamed tissue also demonstrated significant effects on CGRP, which is a relevant biomarker of inflammation and pain.
”The project is based on a mechanism with strong preclinical and clinical validation. We have now been able to show that our potent and selective TrkA-NAM molecules exhibit both analgesic and anti-inflammatory effects in a relevant preclinical model, which are promising results for their further development,” said Dr. Forsell.
”These positive data further strengthen the project and contribute to increased commercial interest. That this is also a mechanism that is not linked to the side effects and addiction problems observed with opioids is important in the context as the medical need for alternative treatments is very great," said Martin Jönsson, CEO of AlzeCure Pharma.
The presentation and abstract are available on AlzeCure's website: https://www.alzecurepharma.se/en/presentations-and-interviews
